Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Chow, Pierce K H ^a,b,c   Poon, Donald Y H ^b   Khin, Maung Win ^d   Singh, Harjit ^e   Han, Ho Seong ^f   Goh, Anthony S W ^a   Choo, Su Pin ^b   Lai, Hee Kit ^a   Lo, Richard H G ^a   Tay, Kiang Hiong ^a   Lim, Teong Guan ^a   Gandhi, Mihir ^c,g   Tan, Say Beng ^c,g   Soo, Khee Chee ^a,b,c  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d Yangon Gastrointestinal and Liver Centre   (Myanmar)

^e Selayang Hospital   (Malaysia)

^f Seoul National University Bundang Hospital   (South Korea)

^g SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; SIR SPHERES; SORAFENIB; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; YTTRIUM;

ABDOMINAL DISTENSION; ACNE; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASCITES; BRACHYTHERAPY; CLINICAL ARTICLE; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FEMALE; FEVER; GINGIVA BLEEDING; HAND FOOT SYNDROME; HEMOPTYSIS; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOALBUMINEMIA; LETHARGY; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PNEUMONIA; QUALITY OF LIFE; RADIATION INJURY; RADIOEMBOLIZATION; RASH; SEPSIS; SKIN INJURY; SKIN TOXICITY; THORAX PAIN; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ARTIFICIAL EMBOLISM; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; LIVER NEOPLASMS; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; TIME;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; QUALITY OF LIFE; TIME FACTORS; YTTRIUM RADIOISOTOPES;

EID: 84897556621     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090909     Document Type: Article

References (38)

1. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma (2010) Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements. J Gastroenterol Hepatol 25: 657-663.
2. Hung H (2005) Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 5: 131-138.
3. Lau WY, Ho S, Leung TW, Chan M, Johnson PJ, et al. (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40: 583-592. (Pubitemid 28104228)
4. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, et al. (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology 138: 52-64.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. for the SHARP Investigators Study Group. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390 and Appendix B (dose reduction guidelines).
7. Cheng JC, Chou CH, Kuo ML, Hsieh CY (2006) Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25: 7009-7018. (Pubitemid 44722069)
8. Chung YL, Jian JJ, Cheng SH, Tsai SY, Chuang VP, et al. (2006) Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res 12: 2706-2715.
9. Zhao JD, Liu J, Ren ZG, Gu K, Zhou ZH, et al. (2010) Maintenance of sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol 5: 12.
10. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, et al. (2007) Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 67: 9443-9454. (Pubitemid 47535934)
11. Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, et al. (2010) Sorafenib and radiation: a promising combination in colorectal cancer. Int J Radiat Oncol Biol Phys 78: 213-220.
12. Li B, Yu J, Wang L, Li C, Zhou T, et al. (2003) Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma. Am J Clin Oncol 26: e92-99.
13. Zhou ZH, Liu LM, Chen WW, Men ZQ, Lin JH, et al. (2007) Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol 80: 194-201. (Pubitemid 47007810)
14. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, et al. (2011) for the EuropeanNetwork on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology 54: 868-78.
15. Chow PKH, Poon DYH, Choo SP, Lai H, Goh A, et al. (2009) for the Asia-Pacific Hepatocellular Carcinoma Trials Group Phase I study of SIR-sphere plus sorafenib as first line treatment in patients with non-resectable Hepatocellular Carcinoma. The Asia-Pacific Hepatocellular Carcinoma Trials Group protocol 05 (AHCC05). J Clin Oncol 21(suppl): abstract e15538.
16. Chow PK, Tai BC, Tan CK, Machin D, Win KM, et al. (2002) for the Asian-Pacific Hepatocellular Carcinoma Trials Group High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 36: 1221-1226. (Pubitemid 35253439)
17. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) EASL Panel of Experts on HCC Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35: 421-430. (Pubitemid 32844200)
18. Liu DM, Salem R, Bui JT, Courtney A, Barakat O, et al. (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16: 911-935. (Pubitemid 40993515)
19. Ho S, Lau WY, Leung TW, Chan M, Ngar YK, et al. (1996) Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 23: 947-952. (Pubitemid 26278795)
20. 90Y Microspheres.Springer, New York; ISBN 978-3-540-35421-5.
21. Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, et al. (2002) Estimating an EQ-5D population value set: the case of Japan. Health Econ 11: 341-353. (Pubitemid 34578418)
22. A'Hern RP (2001) Sample size tables for exact single-stage phase II designs. Stat Med 20: 859-866.
23. Cleveland M (1979) Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 74: 829-836.
24. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, et al. (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III sorafenib Asia-Pacific trial. Eur J Cancer 48: 1452-1465.
25. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, et al. (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29: 3960-3967.
26. Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, et al. (2013) Radioembolization forhepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol 58: 73-80.
27. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, et al. (2013) Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology 57: 1826-1837.
28. Shah RR, Morganroth J, Shah DR (2013) Hepatotoxicity of Tyrosine Kinase Inhibitors Clinical and Regulatory Perspectives. Drug Saf 2013 [In press].
29. EMEA (2013) Nexar (Sorafenib). Summary of product characteristics. Available: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000690/WC500027704.pdf. Accessed 2013 Sept 4.
30. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, et al. (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112: 1538-1546. (Pubitemid 351441166)
31. Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, et al. (2012) Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82: 401-407.
32. Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez-Fraile M, et al. (2013) Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57: 1078-1087.
33. 90Y microsphere administration: resemblance to the Kasabach-Merritt syndrome. J Vasc Interv Radiol 19: 1099-1102.
34. 90Yttrium microsphere therapy for inoperable hepatoma. South Med J 103: 1264-1268.
35. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, et al. (1995) Radiation pneumonitis after selective internal radiation treatment with intraarterial yttrium-90 microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33: 919-924.
36. Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, et al. (2011) Sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma: final results of the SOCRATES trial. J Hepatol 54(suppl 1): S35, abstract 79.
37. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, et al. (2008) The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer 44: 1000-1006.
38. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, et al. (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Subanalysis of a phase III trial. J Hepatol 57: 821-829.